Recent Updates
Recently added Catalysts

Entinostat

Phase 2

Renal Cell Carcinoma | Small molecule | Oncology |Syndax Pharmaceuticals, Inc.|Last Updated: Mar 20, 2025

Success Probability
Subscribe to view
Market & Valuation
Subscribe to view
Trial Design
RandomizedACTIVE_CONTROLLEDDMC
Total Trials1
Total Enrollment46
FDA Designations
No designations recorded
Clinical trial landscape

Entinostat · 16 trials · 40 indications

Phase 2 3Phase 1 13
NCT03501381High Dose IL 2 and Entinostat in RCCRenal Cell Carcinoma
ACTIVE NOT_RECRUITING46 Analytics
NCT00828854Study of the Effect of the Addition of SNDX-275 (Entinostat) to Continued Aromatase Inhibitor (AI) Therapy in Postmenopausal Women With ER+ Breast Cancer Whose Disease is ProgressingER+ Breast Cancer
COMPLETED27 Analytics
NCT00676663Study to Evaluate Exemestane With and Without Entinostat (SNDX-275) in Treatment of Postmenopausal Women With Advanced Breast CancerBreast Cancer
COMPLETED130 Analytics
PHASE2ACTIVE NOT_RECRUITING
High Dose IL 2 and Entinostat in RCC
Renal Cell CarcinomaUnlock trial analytics
PHASE2COMPLETED
Study of the Effect of the Addition of SNDX-275 (Entinostat) to Continued Aromatase Inhibitor (AI) Therapy in Postmenopausal Women With ER+ Breast Cancer Whose Disease is Progressing
ER+ Breast CancerUnlock trial analytics
PHASE2COMPLETED
Study to Evaluate Exemestane With and Without Entinostat (SNDX-275) in Treatment of Postmenopausal Women With Advanced Breast Cancer
Breast CancerUnlock trial analytics
Study Endpoints
Primary Endpoints
Progression Free Survival (PFS)
24 months

Compare PFS between arms. PFS is defined as the time from date of randomization until the criteria for disease progression is met as defined by RECIST 1.1 or death as a result of any cause.

Clinical Benefit Rate (CBR)
6 months

CBR is defined as the percentage of participants who achieved complete response (CR) or partial response (PR) or stable disease (SD) for 6 months as assessed by the investigator based on Response Evaluation Criteria in Solid Tumors (RECIST), version 1.0. CR is defined as the disappearance of all target lesions. PR is defined as at least a 30% decrease in the sum of the longest diameter (LD) of target lesions, taking as reference the baseline sum LD. SD is defined as neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for progressive disease (PD), taking as reference the smallest sum LD since the treatment started.

Progression-free Survival (PFS)
From date of randomization to discontinuation due to disease progression or death up to primary completion date (Median follow-up 6 months)

PFS is defined as the number of months from the date of randomization to the earlier of progressive disease (PD) or death due to any cause.

Identification of a maximum tolerated dose combination (MTDC) of entinostat and capecitabine
During the first cycle of treatment (each cycle is 21 days) for each participant

This will be defined based on the number of "dose limiting toxicities" in participants at each dose level.

Frequency of adverse events (AEs) in participants with high-risk breast cancer after neo-adjuvant therapy
AEs from consent through 30 days following stopping study treatment. Study treatment-related serious adverse events (SAEs) anytime

Frequency of adverse events (AEs) in participants with high-risk BC after neo-adjuvant therapy at the determined MTDC.

Severity (as graded with the Common Terminology Criteria for Adverse Events (CTCAE)) of adverse events (AEs) in participants with high-risk breast cancer after neo-adjuvant therapy
AEs from consent through 30 days following stopping study treatment. Study treatment-related serious adverse events (SAEs) anytime

Severity of adverse events (AEs) in participants with high-risk BC after neo-adjuvant therapy at the determined MTDC.

To evaluate AUC0-t (area under the concentration-time curve) for entinostat in subjects with varying degrees of renal impairment versus healthy matched subjects.
Pre-dose through Day 22

AUC0-t will be computed for all subjects

To evaluate AUC0-inf (area under the concentration-time curve, from time 0 to infinity) for entinostat in subjects with varying degrees of renal impairment versus healthy matched subjects.
Pre-dose through Day 22

AUC0-inf will be computed for all subjects

To evaluate Cmax (maximum observed concentration) for entinostat in subjects with varying degrees of renal impairment versus healthy matched subjects.
Pre-dose through Day 22

Cmax will be computed for all subjects

PK endpoint of AUC0-t (area under the concentration-time curve) for midazolam administered with and without entinostat.
Pre-dose to 24 hours after dosing

AUC0-t for midazolam and 1 OH midazolam will be computed.

PK endpoint of AUC0-inf (area under the concentration-time curve, from time 0 extrapolated to infinity) for midazolam administered with and without entinostat.
Pre-dose to 24 hours after dosing

AUC0-inf for midazolam and 1 OH midazolam will be computed

PK endpoint of Cmax (maximum observed concentration) for midazolam administered with and without entinostat.
Pre-dose to 24 hours after dosing

Cmax for midazolam and 1 OH midazolam will be computed

Phase 2: Progression Free Survival (PFS), as Determined by the Local Investigator Using Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1)
From date of randomization to PD or death due to any cause (maximum exposure: 24 cycles [each cycle = 14 days])

PFS was defined as the number of months from randomization to progressive disease (PD) or death due to any cause, whichever occurred first. PD: At least a 20% increase in the sum of diameters of target lesions, taking as reference the smallest sum on study. In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 millimeters (mm); the appearance of one or more new lesions; and unequivocal progression of existing non-target lesions.

Phase 1b: Number of Participants With at Least One Dose Limiting Toxicity (DLT) Adverse Event (AE)
Day 1 through Day 28 (Cycles 1 and 2)

A DLT was defined as the occurrence of any protocol-specified event within the first 2 cycles of treatment (from Cycle 1 Day 1 through the end of Cycle 2) of entinostat in combination with avelumab that were considered by the investigator to be at least possibly related to study drug.

AUC0-t (area under the concentration-time curve) for entinostat administered with or without omeprazole (Part 1), with or without famotidine (Part 2), or omeprazole with and without acidic beverage
Pre-dose through Day 22
AUC0-inf (area under the concentration-time curve, from time 0 extrapolated to infinity for entinostat administered with or without omeprazole (Part 1), with or without famotidine (Part 2), or omeprazole with and without acidic beverage (Part 3)
Pre-dose through Day 22
Cmax (maximum observed concentration) for entinostat administered with or without omeprazole (Part 1), with or without famotidine (Part 2), or omeprazole with and without acidic beverage (Part 3)
Pre-dose through Day 22
AUC0-t (area under the concentration-time curve, from time 0 to the last observed non-zero concentration (t) for entinostat under fed and fasting conditions
Pre-dose through Day 22
AUC0-inf (area under the concentration-time curve, from time 0 extrapolated to infinity) for entinostat under fed and fasting conditions
Pre-dose through Day 22
Cmax (maximum observed concentration) of entinostat under fed and fasting conditions
Pre-dose through Day 22
AUC%extrap (percent of AUC0-inf extrapolated) of entinostat under fed and fasting conditions
Pre-dose through Day 22
Tmax (time to reach maximum observed concentration) of entinostat under fed and fasted conditions
Pre-dose through Day 22
Kel (apparent terminal elimination rate constant) of entinostat under fed and fasted conditions
Pre-dose through Day 22
T1/2 (apparent terminal elimination half-life) of entinostat under fed and fasted conditions
Pre-dose through Day 22
Changes from baseline in physical exam
Baseline through Day 1
Changes from baseline in vital signs
Baseline through Day 22
Changes from baseline in ECG results
Baseline through Day 22
Changes from baseline in adverse events
Baseline through 14 days after last sample collection
Changes from baseline in clinical laboratory tests
Baseline through Day 1
Incidence of treatment-emergent adverse events (TEAEs), serious adverse events (SAEs), and adverse events (AEs) resulting in the permanent discontinuation of study drug, and deaths occurring within the reporting period required for the study
Each treatment cycle is 21 days. All events will be collected from informed consent through 90 days post-last dose or through 30 days after initiation of new anti-cancer therapy
Changes from baseline in laboratory results
Baseline through 90 day safety follow-up visit
Change from Baseline in Heart Rate (HR)
Baseline (pre-dose) through 24 hours post-dose

Heart rate measured in beats per minute (bpm).

Change from Baseline in Electrocardiogram Procedures
Baseline (pre-dose) through 24 hours post-dose

Change from baseline in QT interval corrected for heart rate (Qtc), PR interval (PR) and QRS complex (QRS).

Change from Baseline in T-Cell Morphology
Baseline (pre-dose) through 24 hours post-dose
Cmax, maximum plasma concentration
Approximately 1 year
Tmax, time at which maximum plasma concentration was observed
Approximately 1 year
AUC0-t, area under the plasma concentration-time curve from time zero to the last measurable concentration
Approximately 1 year
AUC0-inf, area under the plasma concentration-time curve from time zero extrapolated to infinity
Approximately 1 year
T1/2, elimination half-life
Approximately 1 year
lambda z , apparent terminal phase elimination constant (λz)
Approximately 1 year
AUC0-τ where τ=168 hours for entinostat and τ=24 hours for exemestane
Approximately 1 year
Incidence of treatment-emergent adverse events (TEAEs), serious adverse events (SAEs), AEs resulting in the permanent discontinuation of study drug, and deaths occurring within 30-days of the last dose of study drug
Approximately 1 year
Changes from baseline in laboratory, vital signs, and electrocardiogram (ECG) values
Approximately 1 year
Phase 1b: Participants Experiencing DLT
Up to 21 days after Cycle 1 Day 1

Phase 1b employed a classical 3+3 design, with the determination of DLT based on entinostat in combination with atezolizumab within the first cycle of treatment (that is, between Day 1 to Day 21 of Cycle 1). Six participants were required to be treated in a dose level for it to be considered MTD or the Recommended Phase 2 Dose (RP2D). A DLT was defined as the occurrence of specific events, defined in the protocol, that were considered by the investigator to be at least possibly related to study drug using the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events version 4.03.The DLT assessment window (Cycle 1) was the time period between Cycle 1 Day 1 until Cycle 2 Day 1 (expected to be 21 days after Cycle 1 Day 1).

Phase 1b: Determination of the RP2D
Up to 21 days after Cycle 1 Day 1

Phase 1b employed a classical 3+3 design, with the determination of the RP2D based on entinostat in combination with atezolizumab within the first cycle of treatment (that is, between Day 1 to Day 21 of Cycle 1). The RP2D was defined as equal to or less than the preliminary maximum tolerated dose (MTD) and was determined in discussion with the sponsor, the study medical monitor, and dose determination phase investigators. The MTD was defined as the highest dose level at which \<33% of 6 participants experience DLT.

Phase 2 Expansion: Duration of Progression-free Survival (PFS) Using Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1)
Up to 1 year

The duration of PFS, assessed using RECIST 1.1, was used to evaluate the efficacy of entinostat at the RP2D in combination with atezolizumab in participants with advanced triple negative breast cancer (aTNBC). It was defined as the number of months from randomization to the earlier of progressive disease or death due to any cause. One month was considered 30.4375 days. PFS (months) = (Date of Progression or Censoring - Date of Randomization + 1)/30.4375.

Phase 2: Objective Response Rate (ORR), as Assessed Using Immune Response RECIST (irRECIST)
From date of randomization to date of progression (up to 765 days)

The ORR was defined as the percentage of participants with confirmed complete response (CR) or partial response (PR). CR: Complete disappearance of all lesions (whether measurable or not) and no new lesions. All measurable lymph nodes also must have a reduction in short axis to \<10 millimeters (mm). PR: Sum of the diameters (longest for non-nodal lesions, shortest for nodal lesions) of target and new measurable lesions decreases ≥30%. For purposes of analysis, 1 month was considered to be 30.4375 days.

Difference in pharmacokinetics of entinostat when subjects fed or fasted
C1D1 (sequential), D2, 4, 6, 8, 11; C1D15 (sequential), 16, 18, 20, 22 25; C2D1

The pharmacokinetics of entinostat will be analyzed from patient plasma samples: maximum plasma concentration, time of maximum plasma concentration, area under the plasma concentration-time curve from baseline to last measurable concentration and extrapolated to infinity, terminal elimination rate constant.

Identification of Safe-dose for the Phase 2 Double-blind Phase in the Lead-in Phase
Cycle 1 of Lead-in Phase

Safe recommended Phase 2 dose was determined based on dose-limiting toxicities (DLT) in Cycle 1. A DLT was defined as any of the following occurring in Cycle 1: Grade 3 or greater nonhematologic toxicity that was considered related to either entinostat or erlotinib or a Grade 4 hematologic toxicity lasting more than 7 days and/or resulting in a dose delay. Common Terminology Criteria for Adverse Events (CTCAE) version 3.0 scale was used where Grade 1=mild, Grade 2=Moderate, Grade 3=Severe, medically significant, Grade 4=life-threatening and 5=death. The dose that was found to be safe is reported.

4-Month Progression-free Survival (PFS) Rate in the Double-blind Phase
Month 4

PFS rate at 4 months was defined as the percentage of participants who are progression-free at 4 months.

Secondary Endpoints
Objective Response Rate
24 months
Assess Adverse Events
24 months
Duration of response
24 months
Unlock Study Endpoints
Study Design & Arms
AllocationRANDOMIZED
MaskingNONE
ModelPARALLEL
PurposeTREATMENT
Treatment Arms
ArmTypeDescription
High Dose Interleukin 2ACTIVE_COMPARATORHD IL-2 600,000 IU/kg Every 8 hours on Days 1-5 and Days 15-19
High Dose Interleukin 2 plus EntinostatEXPERIMENTALHD IL-2 600,000 IU/kg Every 8 hours on Days 1-5 and Days 15-19 plus Entinostat 5 mg orally every 2 weeks starting Day -14
Entinostat 5 mg + AIEXPERIMENTALEntinostat 5 mg tablet orally every week on Days 1, 8. 15 and 22 of each 28-day treatment cycle in combination with continued treatment with AI therapy at labeled dose and schedule until disease progression or unacceptable toxicity.
Exemestane 25 mg + Entinostat 5 mgEXPERIMENTALExemestane (Aromasin®) 25 mg tablets orally once daily plus an entinostat 5 mg tablet orally once per week on Days 1, 8, 15 and 22 of each 28-day treatment cycle until development of progressive disease (PD) or unacceptable toxicity or closure of the study by the Sponsor, whichever occurred first.
Exemestane 25 mg + PlaceboPLACEBO_COMPARATORExemestane (Aromasin®) 25 mg tablets orally once daily plus a placebo-matching entinostat tablet orally once per week on Days 1, 8, 15 and 22 of each 28-day treatment cycle until development of progressive disease (PD) or unacceptable toxicity or closure of the study by the Sponsor, whichever occurred first.
Entinostat and CapecitabineEXPERIMENTALDose escalation of the combination of entinostat and capecitabine in MBC patients. This dose will be given to MBC patients and to BC patients with residual invasive disease after neoadjuvant chemotherapy and surgery. The dose combinations include: Combination 1: 3 mg/week entinostat, 800 mg/m2 twice a day for 14 days of capecitabine Combination 2: 5 mg/week entinostat, 800 mg/m2 twice a day for 14 days of capecitabine Combination 3: 3 mg/week entinostat, 1000 mg/m2 twice a day for 14 days of capecitabine Combination 4: 5 mg/week entinostat, 1000 mg/m2 twice a day for 14 days of capecitabine If a participant experiences unacceptable side effects, he or she will receive the next lowest dose combination. If he or she is on Combination 1, he or she will stop study treatment.
Mild Renal ImpairmentEXPERIMENTALSubjects with mild renal impairment
Moderate Renal ImpairmentEXPERIMENTALSubjects with moderate renal impairment
Severe Renal ImpairmentEXPERIMENTALSubjects with severe renal impairment
Healthy SubjectsEXPERIMENTALHealthy volunteers mean-matched to the mild, moderate, and severe renal impairment patients
MidazolamOTHERTreatment A: 2 mg of Midazolam administered - Period 1, Day 1 Treatment B: 2 mg of Midazolam with 5 mg Entinostat (after 14 day minimum washout from Period 1, Day 1) - Period 2, Day 1
Entinostat plus AvelumabACTIVE_COMPARATORAvelumab is administered intravenously (IV) on Day 1 of each 14-day cycle in combination with Entinostat administration on Day 1 and Day 8 of each cycle at the Maximum tolerated Dose (MTD)/RP2D as determined in the Phase Ib (Dose Determination) part of the study.
Placebo plus AvelumabPLACEBO_COMPARATORAvelumab is administered intravenously (IV) on Day 1 of each 14-day cycle in combination with placebo administered on Day 1 and Day 8 of each cycle.
OmeprazoleACTIVE_COMPARATORTreatment A: 5mg entinostat on Day 1 Treatment B: 20mg omeprazole for 5 days with 5mg entinostat on Day 1
FamotidineACTIVE_COMPARATORTreatment C: 5mg entinostat on Day 1 Treatment D: 20mg famotidine on Days -1 and 1 with 5mg entinostat on Day 1
Acidic BeverageACTIVE_COMPARATORTreatment E: 20mg omeprazole for 5 days with 5mg entinostat on Day 1 taken with water Treatment F: 20mg omeprazole for 5 days with 5mg entinostat on Day 1 taken with an acidic beverage
Entinostat 5mg in 2-Way CrossoverEXPERIMENTALTreatment A: 5mg entinostat following an overnight fast and followed by a 4-hour fast. Treatment B: 5mg entinostat 2 hours after the completion of a meal and followed by a 1-hour fast.
Entinostat 5mg in 3-Way CrossoverEXPERIMENTALTreatment C: 5mg entinostat following an overnight fast and followed by a 4-hour fast. Treatment D: 5mg entinostat following an overnight fast and 1 hour before the start of a meal. Treatment E: 5mg entinostat 2 hours after the completion of a meal and followed by a 4-hour fast.
ENT 1mg daily with pembro every 3 weeksACTIVE_COMPARATOREntinostat daily in combination with pembrolizumab every three weeks
ENT 5mg weekly with pembro every 3 weeksACTIVE_COMPARATOREntinostat once weekly in combination with pembrolizumab every three weeks
ENT 10mg bi-weekly with pembro every 3 weeksACTIVE_COMPARATOREntinostat once every other week in combination with pembrolizumab every three weeks
EntinostatACTIVE_COMPARATORParticipants received a single oral supratherapeutic dose of 15 mg entinostat under fasted conditions.
PlaceboPLACEBO_COMPARATORParticipants received a single dose of placebo-matching entinostat under fasted conditions.
Cohort 1ACTIVE_COMPARATORCohort 1 will evaluate exemestane's effect on the PK of entinostat. Each treatment cycle is 28 days.
Cohort 2ACTIVE_COMPARATORCohort 2 will enroll when Cohort 1 enrollment is complete. Cohort 2 will evaluate entinostat's effect on the PK of exemestane. Each treatment cycle is 28 days.
Entinostat plus AtezolizumabACTIVE_COMPARATORParticipants in this arm will receive entinostat in combination with atezolizumab. Phase 1b Dose Determination: The initial 3 to 6 participants will receive entinostat at a starting dose of 5 milligrams (mg) (Dose Group 1) on Days 1, 8, and 15 along with atezolizumab 1200 mg via intravenous (IV) infusion on Day 1 of each 21-day cycle. If the 5 mg dose exceeds the maximum tolerated dose (MTD), then a 3 mg dose of entinostat (Dose Group -1) will be evaluated in the same manner. If the -1 dose level exceeds the MTD, then a 2 mg dose of entinostat (Dose Group -2) will be evaluated. Phase 2 Dose Expansion: Participants will receive the RP2D identified in the Dose Determination Phase.
Placebo plus AtezolizumabPLACEBO_COMPARATORParticipants in this arm will receive placebo in combination with atezolizumab 1200 mg.
Phase 1b (Dose Escalation): Entinostat 3 mg Weekly + PembrolizumabEXPERIMENTALParticipants with NSCLC will receive entinostat 3 mg administered orally weekly (Days 1, 8, and 15 of each 21-day cycle) along with pembrolizumab 200 mg via intravenous (IV) infusion once every 3 weeks (Day 1 of each 21-day cycle).
Phase 1b (Dose Escalation): Entinostat 5 mg Weekly + PembrolizumabEXPERIMENTALParticipants with NSCLC will receive entinostat 5 mg administered orally weekly (Days 1, 8, and 15 of each 21-day cycle) along with pembrolizumab 200 mg via IV infusion once every 3 weeks (Day 1 of each 21-day cycle).
Phase 1b (Dose Confirmation): Entinostat 5 mg Weekly + PembrolizumabEXPERIMENTALParticipants with NSCLC will receive entinostat 5 mg administered orally weekly (Days 1, 8, and 15 of each 21-day cycle) along with pembrolizumab 200 mg via IV infusion once every 3 weeks (Day 1 of each 21-day cycle).
Phase 2, Cohort 1: Entinostat 5 mg Weekly + PembrolizumabEXPERIMENTALParticipants with NSCLC with squamous cell or adenocarcinoma histology who had not been treated with a programmed cell death receptor-1 (PD-1)- or programmed cell death ligand-1 (PD-L1)-blocking antibody, will receive entinostat 5 mg administered orally weekly (Days 1, 8, and 15 of each 21-day cycle) along with pembrolizumab 200 mg via IV infusion once every 3 weeks (Day 1 of each 21-day cycle).
Phase 2, Cohort 2: Entinostat 5 mg Weekly + PembrolizumabEXPERIMENTALParticipants with NSCLC (any histology) who has previously been treated with and unequivocally progressed on either a PD-1- or PD-L1-blocking antibody, will receive entinostat 5 mg administered orally weekly (Days 1, 8, and 15 of each 21-day cycle) along with pembrolizumab 200 mg via IV infusion once every 3 weeks (Day 1 of each 21-day cycle).
Phase 2, Cohort 3: Entinostat 5 mg Weekly + PembrolizumabEXPERIMENTALParticipants with melanoma who has previously been treated with and unequivocally progressed on either a PD-1- or PD-L1-blocking antibody, will receive entinostat 5 mg administered orally weekly (Days 1, 8, and 15 of each 21-day cycle) along with pembrolizumab 200 mg via IV infusion once every 3 weeks (Day 1 of each 21-day cycle).
Phase 2, Cohort 4: Entinostat 5 mg Weekly + PembrolizumabEXPERIMENTALParticipants with CRC (mismatch repair-proficient) who had not been previously treated with a PD-1- or PD-L1-blocking antibody, received entinostat 5 mg administered orally weekly (Days 1, 8, and 15 of each 21-day cycle) along with pembrolizumab 200 mg via IV infusion once every 3 weeks (Day 1 of each 21-day cycle).
entinostat C1D1 fedEXPERIMENTALEntinostat: Beginning C1D1 fed; C1D15 fasted. Erlotinib: NSCLC pts beginning C2D1,150 mg, po, qd. Exemestane: Breast cancer pts beginning C2D1,25 mg, po, qd.
entinostat C1D1 fastedEXPERIMENTALEntinostat: Beginning C1D1 fasted; C1D15 fed. Erlotinib: NSCLC pts beginning C2D1,150 mg, po, qd. Exemestane: Breast cancer pts beginning C2D1,25 mg, po, qd.
Lead-in Phase: Erlotinib + Entinostat 5 mgEXPERIMENTALErlotinib 150 mg, tablets, orally, daily plus entinostat 5 mg, tablets, orally, on Days 1 and 15 of each 28-day cycle until disease progression or intolerable toxicities for up to 6 cycles in the Lead-in Phase.
Lead-in Phase: Erlotinib + Entinostat 10 mgEXPERIMENTALErlotinib 150 mg tablets, orally, daily plus entinostat 10 mg, tablets, orally, on Days 1 and 15 of each 28-day cycle until disease progression or intolerable toxicities for up to 6 cycles in the Lead-in Phase.
Double-blind Phase: Erlotinib + Entinostat 10 mgEXPERIMENTALErlotinib 150 mg, tablets, orally, daily plus entinostat 10 mg, tablets, orally, on Day 1 and 15 of a 28-day cycle until disease progression or intolerable toxicities for up to 6 cycles in the Double-blind Phase.
Double-blind Phase: Erlotinib + PlaceboPLACEBO_COMPARATORErlotinib 150 mg, tablets, orally, daily plus placebo matching entinostat, tablets, orally, on Days 1 and 15 of each 28-day cycle until disease progression or intolerable toxicities for up to 6 cycles in the Double-blind Phase.
Crossover Phase: Erlotinib + Entinostat 10 mgEXPERIMENTALParticipants in the Double-blind Phase Erlotinib + Placebo arm who experienced disease progression crossed over to receive open-label erlotinib 150 mg, tablets, orally, daily plus entinostat 10 mg, tablets, orally, on Days 1 and 15 of each 28-day cycle until disease progression or intolerable toxicities.
Interventions
NameTypeDescription
EntinostatDRUGEntinostat should be taken 1-2 hours prior to the HD IL-2 infusion. Dose reductions for entinostat should be followed. Entinostat will continue after high dose IL-2 every 2 weeks
Interleukin-2DRUGIn the event of clinical benefit after a course of HD IL-2 (stable disease or tumor shrinkage) patients will receive a second treatment course of HD IL-2 therapy. Patients with evidence of tumor shrinkage after the 2nd HD IL-2 treatment course may receive a 3rd treatment course of HD IL-2.
Aromatase Inhibitor (AI) TherapyDRUGAI therapy at labeled dose and schedule as prescribed in clinical practice. AI therapies include: Arimidex® (anastrozole) 1 mg/day by mouth (PO), Fermara® (letrozole) 2.5 mg/day PO , Aromasin® (exemestane) 25 mg/day PO.
exemestaneDRUGExemestane 25 mg tablet orally once daily
PlaceboDRUGPlacebo-matching entinostat tablet orally once per week
CapecitabineDRUGIn metastatic breast cancer patients, capecitabine will be taken by mouth starting at 800 mg/m2 twice a day for 14 days per cycle and increase to 1000 mg/m2 (for 14 days per cycle) in the absence of unacceptable side effects. The safe dose (when combined with capecitabine) will be confirmed in additional metastatic breast cancer patients and breast cancer patients with residual invasive disease following neoadjuvant chemotherapy and surgery.
MidazolamDRUGbenzodiazepine central nervous system (CNS) depressant
avelumabDRUGA fully human antibody of the immunoglobulin (Ig) G1 isotype that targets and blocks Programmed death-ligand 1 (PD-L1), the ligand for Programmed cell death protein 1 (PD-1) receptor.
OmeprazoleDIETARY_SUPPLEMENTProton pump inhibitor
FamotidineDIETARY_SUPPLEMENTHistamine-2 blocker
PembrolizumabDRUGA selective humanized monoclonal antibody (mAb)
AtezolizumabDRUGA humanized, engineered monoclonal antibody of IgG1 isotype against the protein programmed cell death ligand 1 (PD-L1).
ErlotinibDRUGErlotinib: NSCLC pts beginning C2D1,150 mg, po, qd.
Unlock Study Design Details
Eligibility Criteria
Age Range18 Years to N/A
SexALL
Healthy VolunteersNo
Study Sites5

Inclusion Criteria: * Age ≥ 18 years at the time of consent. * ECOG Performance Status of 0 within 14 days prior to registration. * Life expectancy of greater than 6 months. * Patients must have pathological diagnosis of renal cell carcinoma that is metastatic or surgically unresectable. The histol...

Countries:United StatesIrelandUnited KingdomCanadaCzechiaHungaryRussiaGeorgia
Unlock Eligibility Criteria
Recent Changes (Last 90 Days)
LOWMay 26, 2026NCT03501381primaryCompletionDate: changed
LOWMay 24, 2026NCT03501381studyFirstPostDate: changed